Loading
A phase 1/2 trial of single dose of CNCT19 in acute lymphoblastic leukaemia, run by Juventas Cell Therapy Ltd., now recruiting.
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric) is a phase 1/2 interventional study registered as NCT05667506 by Juventas Cell Therapy Ltd., with 47 participants planned, started 2023-02-07 and due to reach its primary completion in 2025-05-30. Interventions recorded: single dose of CNCT19.
Shares Juventas Cell Therapy, Inaticabtagene autoleucel, CAR-T cell therapy, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Juventas Cell Therapy, Inaticabtagene autoleucel, CAR-T cell therapy and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.
Shares CAR-T cell therapy, Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.